High-rolling investors have positioned themselves bullish on Viking Therapeutics VKTX, and it's important for retail traders to take note. \This activity came to our attention today through Benzinga's tracking of publicly available options data. The identities of these investors are uncertain, but such a significant move in VKTX often signals that someone has privileged information.
Today, Benzinga's options scanner spotted 9 options trades for Viking Therapeutics. This is not a typical pattern.
The sentiment among these major traders is split, with 44% bullish and 33% bearish. Among all the options we identified, there was one put, amounting to $57,349, and 8 calls, totaling $320,592.
Projected Price Targets
Taking into account the Volume and Open Interest on these contracts, it appears that whales have been targeting a price range from $30.0 to $100.0 for Viking Therapeutics over the last 3 months.
Insights into Volume & Open Interest
In terms of liquidity and interest, the mean open interest for Viking Therapeutics options trades today is 1801.8 with a total volume of 3,253.00.
In the following chart, we are able to follow the development of volume and open interest of call and put options for Viking Therapeutics's big money trades within a strike price range of $30.0 to $100.0 over the last 30 days.
Viking Therapeutics Option Volume And Open Interest Over Last 30 Days
Noteworthy Options Activity:
| Symbol | PUT/CALL | Trade Type | Sentiment | Exp. Date | Ask | Bid | Price | Strike Price | Total Trade Price | Open Interest | Volume |
|---|---|---|---|---|---|---|---|---|---|---|---|
| VKTX | PUT | SWEEP | BULLISH | 01/16/26 | $6.3 | $6.1 | $6.1 | $30.00 | $57.3K | 103 | 95 |
| VKTX | CALL | SWEEP | BEARISH | 09/20/24 | $3.7 | $3.3 | $3.7 | $55.00 | $53.9K | 869 | 287 |
| VKTX | CALL | TRADE | NEUTRAL | 11/15/24 | $5.1 | $4.7 | $4.9 | $70.00 | $49.0K | 4.0K | 102 |
| VKTX | CALL | SWEEP | BEARISH | 09/20/24 | $3.6 | $3.4 | $3.5 | $55.00 | $47.3K | 869 | 1.6K |
| VKTX | CALL | SWEEP | NEUTRAL | 09/20/24 | $3.7 | $3.3 | $3.7 | $55.00 | $44.4K | 869 | 20 |
About Viking Therapeutics
Viking Therapeutics Inc is a healthcare service provider. The company specializes in the area of biopharmaceutical development focused on metabolic and endocrine disorders. The company's clinical program pipeline consists of VK2809, VK5211, VK0214 products. VK2809 and VK0214 are orally available, tissue and receptor-subtype selective agonists of the thyroid hormone receptor beta. VK5211 is an orally available, non-steroidal selective androgen receptor modulator.
Following our analysis of the options activities associated with Viking Therapeutics, we pivot to a closer look at the company's own performance.
Present Market Standing of Viking Therapeutics
- With a volume of 1,459,984, the price of VKTX is up 3.93% at $56.26.
- RSI indicators hint that the underlying stock is currently neutral between overbought and oversold.
- Next earnings are expected to be released in 44 days.
Options are a riskier asset compared to just trading the stock, but they have higher profit potential. Serious options traders manage this risk by educating themselves daily, scaling in and out of trades, following more than one indicator, and following the markets closely.
If you want to stay updated on the latest options trades for Viking Therapeutics, Benzinga Pro gives you real-time options trades alerts.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
